Drug Name: Truqap Active Ingredient: capivasertib Indication: An AKT inhibitor used in combination with fulvestrant for the treatment of advanced HR-positive breast cancer Approval Date: 11/16/2023 Company: AstraZeneca More: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-capivasertib-fulvestrant-breast-cancer
Drug Name: Augtyro Active Ingredient: repotrectinib Indication: To treat ROS1-positive non-small cell lung cancer Approval Date: 11/15/2023 Company: Bristol-Myers Squibb Company More: https://accessdata.fda.gov/drugsatfda_docs/label/2023/218213s000lbl.pdf
Drug Name: Defencath Active Ingredient: taurolidine, heparin Indication: To reduce the incidence of catheter-related bloodstream infections in adults with kidney failure receiving chronic hemodialysis through a central venous catheter (Catheter…
Drug Name: Fruzaqla Active Ingredient: fruquintinib Indication: To treat refractory, metastatic colorectal cancer Approval Date: 11/8/2023 Company: Takeda Pharmaceuticals America, IncMore: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217564s000lbl.pdf
Drug Name: Loqtorzi Active Ingredient: toripalimab-tpzi Indication: To treat recurrent or metastatic nasopharyngeal carcinoma when used together with or following other therapies Approval Date: 10/27/2023 Company: Coherus BioSciences, Inc More:…
Drug Name: Agamree Active Ingredient: vamorolone Indication: To treat Duchenne muscular dystrophy Approval Date: 10/26/2023 Company: Santhera Pharmaceuticals (USA), Inc More: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215239s000lbl.pdf
Drug Name: Omvoh Active Ingredient: mirikizumab-mrkz Indication: To treat ulcerative colitis Approval Date: 10/26/2023 Company: Eli Lilly and Company More: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761279s000lbl.pdf
Drug Name: Bimzelx Active Ingredient: bimekizumab Indication: To treat moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy Approval Date: 10/17/2023 Company: UCB, Inc…
Drug Name: Zilbrysq Active Ingredient: zilucoplan Indication: To treat moderately to severely active ulcerative colitis in adults Approval Date: 10/17/2023 Company: UCB, Inc. More: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216834s000lbl.pdf
Drug Name: Velsipity Active Ingredient: etrasimod Indication: To treat moderately to severely active ulcerative colitis in adults Approval Date: 10/12/2023 Company: Pfizer Inc More: https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-fda-and-ema-acceptance-etrasimod